By Myles Starr
The Inflation Reduction Act (IRA), which has made brand-name medications more affordable, also has yielded a key workflow benefit for specialty pharmacists: They now need to rely less on patient assistance programs (PAPs) when shielding patients from the financial toxicity that can accrue from hematology, oncology and other high-cost medications.
JANUARY 2, 2025